Discovery

Our Discovery Platform was developed to support need to streamline corporate performance while creating unique data about industries (products and services), markets (GeoEconoMetrics), and workers (especially knowledge worker) that can be used to support the deployment of AI technologies. Given the breadth of data from our development partner TALON Health Tech, we identified huge opportunity to analyze disease progression across the US healthcare market. To identify markets for epigenetic and nutraceutical products we did a deep dive into specific types of diseases where we could map progression against US demographics. Based on our inital findings, we realized we could expand our analysis to bring vital new information to market to learn more about disease proliferation based on all kinds of demographic and geographic information.

Based on the scalability of our platform we also identified different ways to determine impact new treatments and remedies could have on the US healthcare market. Discovery work on any type of disease is possible due to the fact that we can work through trillion of raw data elements with AI to identify and map patterns of proliferation over time. Given the hierarchial structure of our source data, we realized we could expand our insight of disease progression globally to model healthcare information to evaluate, assess and value how new treatments and remedies derived from molecules and compounds (plant, animal and mineral) could be used to combat disease.

Disease Progression Analysis (Example)

Focus: Myelodysplastic Syndrome / Acute Myeloid Leukemia

Step 1 – Extract patient/provider procedure codes/names associated with MDS and AML to identify “instances” where patients have been tested, diagnosed and treated based on disease progression from detection, remission or death.

Step 2 – Analyze patient records associated with MDS / AML to develop unique demographic data encompassing the entire US market based on age, gender, locations, carriers, providers, practitioners, procedure prices vs. actual costs.

Step 3 – Apply advanced AI to enable probability assessments based on sequencing events from initial diagnosis through disease progression to value cures such as 6-Shogaols to determine patient impact, quality of life value based on probable or likely outcomes.

Step 4 – Provide exhaustive analysis using a proprietary value index to measure patient quality of life vs. cost vs. probable outcomes based on current practices versus epigenetics and unique cures to arrest disease and create favorable results.

Step 5 – Provide detailed market analysis initially in the US based on patient profile analysis, stages of disease progression, demographics and instances of disease based on locations, patients care / outcomes to value market opportunities.

Step 6 – Expand market assessment globally using advanced AI applied across countries, regions, markets, and communities using geoeconometrics to assess cultures, environments, quality of life, stress and other healthcare factors.

Step 7 – Extend analysis using the human genome and DNA analysis to support early detection to increase preventive measures based on new cures, procedures and practices that will impact patient healthcare outcomes globally.

Procedure Codes associated with MS/AML

Procedure Code: 81175 - ASXL1 GENE ANALYSIS FULL GENE SEQUENCE ASXL1 (additional sex combs like 1, transcriptional regulator) (e.g., myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence

Procedure Code: 81176 - ASXL1 GENE ANALYSIS TARGETED SEQ ANALYSIS ASXL1 (additional sex combs like 1, transcriptional regulator) (e.g., myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (e.g., exon 12)

Procedure Code: 81206 - BCR/ABL1 Translocation Analysis, Major Breakpoint BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative

Procedure Code: 81207 - BCR/ABL1 Translocation Analysis, Minor Breakpoint BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative

Procedure Code: 81236 - EZH2 GENE ANALYSIS FULL GENE SEQUENCE EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (e.g., myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence

Procedure Code: 81218 - CEBPA gene analysis, full sequence CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (e.g., acute myeloid leukemia), gene analysis, full gene sequence

Procedure Code: 81245 - FLT3 GENE ANALYSIS INTERNAL TANDEM DUP VARIANTS FLT3 (FMS-RELATED TYROSINE KINASE 3) (EG, ACUTE MYELOID LEUKEMIA), GENE ANALYSIS

Procedure Code: 81246 - FLT3 GENE ANLYS TYROSINE KINASE DOMAIN VARIANTS FLT3 (FMS-RELATED TYROSINE KINASE 3) (EG, ACUTE MYELOID LEUKEMIA), GENE ANALYSIS

Procedure Code: 81310 - NPM1 Analysis NPM1 (nucleophosmin) (e.g., acute myeloid leukemia) gene analysis, exon 12 variants

Procedure Code: 81334 - RUNX1 GENE ANALYSIS TARGETED SEQUENCE ANALYSIS RUNX1 (runt related transcription factor 1) (e.g., acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (e.g., exons 3-8)

Procedure Code: G9123 - ONC DX CML CHRONIC PHASE Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or bcr-abl positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)

Procedure Code: G9124 - ONC DX CML ACCELER PHASE Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or bcr-abl positive; accelerated phase not in hematologic cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)

Procedure Code: G9125 - ONC DX CML BLAST PHASE Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or bcr-abl positive; blast phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)

Procedure Code: G9126 - ONC DX CML REMISSION Short description: Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or bcr-abl positive; in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)

Procedure Code: G9139 - ONC DX CML DX STATUS UNKNOWN Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or bcr-abl positive; extent of disease unknown, staging in progress, not listed (for use in a Medicare-approved demonstration project)